(Q24247988)

https://api.crossref.org/works/10.1002%2F14651858.CD003834

Pharmacotherapy of impaired affect in recovering schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

A comparison of lithium carbonate and chlorpromazine in the treatment of excited schizo-affectives. Report of the Veterans Administration and National Institute of Mental Health collaborative study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

Lithium in tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

Antipsychotic effects of lithium in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

Synergism of combined lithium-neuroleptic therapy: a double-blind, placebo-controlled case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

Effect of lithium on neuroleptic-induced tardive dyskinesia compared with placebo in a double-blind cross-over trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

Factors associated with treatment success in lithium carbonate prophylaxis. Report of the Veterans Administration and National Institute of Mental Health collaborative study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

An Inventory for Measuring Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

When Symptoms Persist: Choosing Among Alternative Somatic Treatments for Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

Meta-analysis. Unresolved issues and future developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

Dosage of haloperidol for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

A controlled dose comparison of haloperidol in newly admitted schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

Lithium as a prophylactic agents. Its effect against recurrent depressions and manic-depressive psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

The phenomenology of mania. A new look at some old patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Psychoactive drugs in mania. A controlled comparison of lithium carbonate, chlorpromazine, and haloperidol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Toward the validation of RDC schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Lithium attenuates the activation-euphoria but not the psychosis induced by d-amphetamine in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Lithium and chlorpromazine: A controlled crossover study of hyperactive severely disturbed young children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Addition of lithium to haloperidol in non-affective, antipsychotic non-responsive schizophrenia: a double blind, placebo controlled, parallel design clinical trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Lithium vs carbamazepine in the maintenance treatment of schizoaffective disorder: a randomised study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Dropout rates in randomised antipsychotic drug trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Lithium and haloperidol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Target symptoms in lithium carbonate therapy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Correlates of lithium response in psychotic-affective syndromes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD003834

1 reference

7 January 2021

d-Amphetamine raises serum prolactin in man: Evaluations after chronic placebo, lithium and pimozide treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Lithium and chlorpromazine in psychotic inpatients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Lithium response and psychoses: A double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Lithium and lecithin in tardive dyskinesia: an update

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Antipsychotic drugs, lithium, carbamazepine, and abnormal diurnal weight gain in psychosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Controlled evaluation of lithium and chlorpromazine in the treatment of manic states: An interim report

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

A pharmacogenetic case report: lithium-responsive postpsychotic antisocial behavior

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

The Northwick Park "functional" psychosis study: diagnosis and treatment response.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Drug response patterns as a basis of nosology for the mood-incongruent psychoses (the schizophrenias)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Failure of lithium treatment in established tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Psychological test for psychopathology.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Evidence of ten psychotic syndromes.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Lithium treatment of psychotic children and adolescents. A controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

A standardized psychiatric assessment scale for rating chronic psychotic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Lithium carbonate in chronic schizophrenia ? a brief trial of lithium carbonate added to neuroleptics for treatment of resistant schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Lithium addition to neuroleptic treatment in chronic schizophrenia: a randomized, double-blind, placebo-controlled, cross-over study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

The treatment of manic psychoses by the administration of lithium salts

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Deanol, lithium and placebo in the treatment of tardive dyskinesia. A double-blind crossover study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Manic-Depressive Illness and Acute Schizophrenia: A Clinical, Family History, and Treatment-Response Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

"Schizoaffective disorder": an invalid diagnosis? A comparison of schizoaffective disorder, schizophrenia, and affective disorder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Physostigmine and lithium response in the schizophrenias

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Predictors of response to lithium in patients with psychoses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

The Northwick Park 'Functional' Psychosis Study. Phase 2: maintenance treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Use of carbamazepine in acute psychosis: a controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Adjunctive carbamazepine or lithium carbonate in therapy-resistant chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Comparison of serum levels of two sustained- release preparations of lithium carbonate

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Comparative Effects of Lithium and Chlorpromazine in the Treatment of Acute Manic States

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

A Controlled Study of Lithium vs. Chlorpromazine in Acute Schizophrenics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

A Checklist for the Diagnosis of Schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

The effectiveness of lithium in affective and schizo-affective psychoses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Further Report on Prophylactic Lithium in Recurrent Affective Disorders

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Trials of Lithium, Chlorpromazine and Amitriptyline in Schizoaffective Patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Lithium treatment in post-psychotic depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Impact of lithium therapy on core psychotic symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Lithium combined with haloperidol in schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorders. A meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021

Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003834

7 January 2021